IGF-1, Nutrition, and Fasting: What Diet Actually Does to Your Levels

Why Nutrition Is the Dominant Short-Term Regulator of IGF-1

IGF-1 is primarily synthesized in the liver in response to growth hormone (GH) signaling, but the liver's capacity to respond to GH depends on nutritional state. Two factors matter most: total caloric availability and dietary protein. Carbohydrate and fat intake play secondary roles largely through their effects on insulin. This means a single week of aggressive dieting can make your IGF-1 look like a GH-deficient patient's lab even if your pituitary is perfectly healthy.

The Hepatic GH Resistance Mechanism

During caloric restriction or protein deficiency, the liver down-regulates the GH receptor and its post-receptor signaling pathway (JAK2-STAT5b). The result is a state called "acquired GH resistance": GH pulses continue normally from the pituitary, but the liver cannot translate them into IGF-1 production. Thissen et al. (1994) characterized this mechanism precisely, demonstrating that the block is post-receptor rather than at the level of GH binding. [1]

This has a direct clinical implication. If you draw an IGF-1 during a 48-hour fast or the second week of an 800-kcal cut, the number tells you almost nothing about your baseline GH axis. The lab must be drawn under stable dietary conditions to be interpretable.

Insulin's Role as a Permissive Co-Factor

Insulin is a permissive signal for hepatic IGF-1 synthesis. Low insulin (as seen in fasting, very-low-carbohydrate diets, or caloric restriction) reduces the liver's responsiveness to GH. A controlled crossover study published in the Journal of Clinical Endocrinology and Metabolism showed that insulin infusion in GH-deficient patients partially restored IGF-1 generation, confirming the co-factor relationship. [2] This is why a ketogenic diet maintained at adequate protein may suppress IGF-1 less than a calorie-matched low-carbohydrate, low-protein approach.

How Fasting Changes IGF-1: Timeline and Magnitude

Fasting is the most dramatic dietary suppressor of IGF-1. The degree of suppression depends on fast duration and baseline nutritional status.

Short Fasts (24 to 72 Hours)

A 5-day fast in healthy adults reduced IGF-1 from a mean of 226 ng/mL to 97 ng/mL, a 57% decline, while GH secretion actually increased during the same period. [3] This dissociation between rising GH and falling IGF-1 is the clearest possible demonstration of acquired hepatic GH resistance. For someone on ipamorelin/CJC-1295 or sermorelin, this means a fast-day IGF-1 draw will underestimate the peptide's effect on the axis.

Prolonged Caloric Restriction

In the CALERIE-2 trial (N=218), participants randomized to 25% caloric restriction for 24 months showed sustained reductions in IGF-1 of approximately 20 to 30% compared to ad libitum controls. [4] CALERIE-2 was a landmark study of caloric restriction in non-obese humans, and the IGF-1 reduction was one of several biomarkers associated with putative longevity pathway activation (reduced mTOR, reduced oxidative stress markers).

Severe restriction below 1,200 kcal/day in women or 1,500 kcal/day in men tends to push IGF-1 below 100 ng/mL in otherwise healthy adults, a level that, if sustained, may impair muscle protein synthesis, bone turnover, and immune function. [5]

Recovery After Fasting

Refeeding raises IGF-1, but the lag matters. After a 7-day fast, IGF-1 returned to baseline values within 2 to 4 weeks of normal eating in one controlled refeeding study. [6] Draw your next IGF-1 lab no sooner than three weeks after ending a prolonged fast or a very-low-calorie protocol if you want a stable, interpretable value.

Dietary Protein: The Single Strongest Modifiable Dietary Variable

Protein intake has a stronger dose-response relationship with IGF-1 than any other macronutrient. This is because amino acids (particularly branched-chain amino acids and methionine) are direct substrates for both liver protein synthesis and the signaling cascades that upregulate IGF-1 gene expression.

Protein Restriction and IGF-1 Suppression

A controlled feeding study by Clemmons et al. Showed that reducing dietary protein from 1.0 g/kg to 0.4 g/kg per day lowered serum IGF-1 by approximately 30% over 4 weeks, while GH pulse frequency and amplitude were unchanged. [7] The suppression was not about GH availability; it was about the raw material and signaling environment the liver needed to make IGF-1.

In populations practicing severe protein restriction (e.g., macrobiotic diets with <0.5 g/kg/day), IGF-1 values are often below 120 ng/mL regardless of age. Studies comparing vegan athletes to omnivore athletes at matched caloric intakes consistently show lower IGF-1 in vegans, primarily attributable to lower total protein and lower leucine density rather than any specific plant compound. [8]

High-Protein Diets and IGF-1 Elevation

Increasing protein above maintenance (1.6 to 2.2 g/kg/day as recommended for resistance-trained individuals) can raise IGF-1 by 15 to 25% above a moderate-protein baseline. A randomized crossover study comparing 0.8 g/kg vs. 1.6 g/kg protein diets (calories matched) produced an IGF-1 difference of approximately 40 ng/mL after six weeks. [9] For someone trying to optimize IGF-1 on a peptide protocol, protein adequacy may matter as much as the peptide dose itself.

Methionine Restriction: The Longevity-Medicine Debate

Methionine restriction is a subject of active research in longevity medicine. In rodent models, reducing methionine intake by 80% extends median lifespan by 30 to 40% and reduces IGF-1 markedly. [10] Whether this translates to humans is genuinely uncertain. Epidemiological data from the Adventist Health Study-2 (N=96,000+) show that vegans, who consume roughly 30 to 50% less methionine than omnivores, have lower cancer incidence rates. But lower IGF-1 in that population also co-occurs with lower protein intake broadly, making methionine the independent variable difficult to isolate. [11]

The HealthRX clinical framework for interpreting IGF-1 in the context of protein intake:

• Below 0.8 g/kg/day: expect IGF-1 suppression of 20 to 40%; any IGF-1 draw under these conditions should be labeled as "nutritionally suppressed" and not used to dose GH or peptides.
• 0.8 to 1.2 g/kg/day: standard reference range applies; this is the dietary state used to establish most lab reference intervals.
• Above 1.6 g/kg/day: IGF-1 may run 10 to 25% above age-matched norms physiologically; this is not pathological if GH axis is otherwise normal.

IGF-1 Normal Range and Optimal Targets

How Reference Ranges Are Built

Commercial lab reference ranges for IGF-1 are age- and sex-stratified because IGF-1 peaks in adolescence (commonly 300 to 700 ng/mL at age 14 to 18) and declines progressively through adulthood. By age 40, the reference range at most large-reference labs sits between roughly 101 to 267 ng/mL for men and 94 to 252 ng/mL for women. By age 60, those ranges shift downward to approximately 75 to 212 ng/mL. [12]

These ranges describe the central 95% of a tested population, not an optimal target. A 55-year-old in the lowest quintile of that range is statistically "normal" but may be experiencing symptoms of relative IGF-1 deficiency (fatigue, reduced lean mass, impaired recovery) that a clinician on a GH axis protocol would treat.

Longevity-Medicine Optimal Range

The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency states that in treated patients, "the goal IGF-1 should be in the normal range for age and sex, and many clinicians target the upper half of the normal range." [13] In longevity and anti-aging medicine, some practitioners target a mid-to-upper-normal range of approximately 150 to 250 ng/mL for adults in their 40s through 60s, based on observational data associating those levels with better body composition and lower frailty scores.

A note of caution: very high IGF-1 (above 300 ng/mL in adults, sustained) has been associated with modestly elevated risk for certain cancers, particularly breast and prostate, in prospective cohort data. The Endogenous Hormones and Breast Cancer Collaborative Group analysis (N=17,330 cases) found a 28% relative increase in breast cancer risk per standard deviation increase in IGF-1 above the population mean. [14] This data point does not establish cause, but it informs why most clinicians avoid targeting the very top of the range without clear clinical indication.

IGF-1 in GH Peptide Therapy

Sermorelin, ipamorelin combined with CJC-1295, and tesamorelin all work by stimulating pulsatile GH release, which then drives hepatic IGF-1 synthesis. The FDA-approved tesamorelin label (Egrifta, 2 mg SC daily) cites mean IGF-1 increases of approximately 90 to 100 ng/mL over 26 weeks in HIV-associated lipodystrophy trials. [15] Off-label use for age-related GH decline typically produces smaller IGF-1 responses (20 to 60 ng/mL above baseline) because baseline GH secretory capacity is lower.

Critically, if a patient is under-eating protein or in a caloric deficit, the peptide's IGF-1 effect will be blunted. A patient on ipamorelin/CJC-1295 who is also doing intermittent fasting with a low-protein eating window may see virtually no IGF-1 rise despite adequate peptide dosing. Protein intake should be confirmed adequate before concluding a peptide dose is insufficient.

Specific Diets and Their Effects on IGF-1

Intermittent Fasting Protocols

The most widely practiced IF schedules (16:8 and 5:2) produce variable IGF-1 effects depending almost entirely on what happens during the eating window. A 16:8 protocol with 160 g of protein daily will show minimal IGF-1 suppression compared to baseline. The same fasting schedule with under 60 g of protein per day may suppress IGF-1 by 15 to 25%. [16]

The 5:2 protocol (two 500-kcal days per week) produces transient IGF-1 dips on fast days, but weekly averages may be only modestly lower than continuous feeding if protein intake on eating days is adequate. A 12-week randomized trial comparing 5:2 to continuous energy restriction (N=107) found no significant IGF-1 difference between arms when total protein intake was matched. [17]

Ketogenic Diets

A ketogenic diet that meets protein targets (1.0 to 1.6 g/kg/day) has a modest suppressive effect on IGF-1, largely attributable to reduced insulin. Studies in epilepsy populations using classical ketogenic diets (high fat, protein-restricted to 1 g/kg/day) show IGF-1 values 15 to 20% below age-matched controls. [18] Protein-adequate ketogenic diets show smaller differences, suggesting that protein adequacy, not ketosis per se, determines most of the IGF-1 signal.

Vegan and Plant-Based Diets

As noted, vegan diets consistently produce lower IGF-1 than omnivore diets at matched calories, with the difference averaging 20 to 30 ng/mL in cross-sectional studies. [19] This is not a reason to avoid plant-based eating, but it does mean that a vegan patient's IGF-1 lab needs nutritional context before being interpreted. A well-constructed vegan diet hitting 1.4 g/kg/day of protein through legumes, tofu, seitan, and supplementation will suppress IGF-1 far less than a low-protein vegan pattern.

Pre-Lab Instructions: Drawing a Clinically Meaningful IGF-1

An IGF-1 drawn under the wrong conditions is not just uninformative. It can lead to incorrect dosing decisions. The following conditions should be met for a stable, interpretable IGF-1:

• No prolonged fasting. Draw the lab after at least two weeks of stable dietary intake. Avoid drawing within 72 hours of any fast longer than 18 hours.
• Stable protein intake. Protein intake should be at your typical level for at least 7 days before the draw.
• Consistent peptide or GH dosing. Draw 24 hours after your last peptide dose if monitoring therapy. Some protocols call for 12-hour post-dose draws; follow your prescribing clinician's specific instructions.
• Morning fasting draw. Most labs use an overnight fast (8 to 12 hours) specifically for IGF-1, which standardizes the insulin environment without invoking prolonged nutritional deprivation. A 12-hour overnight fast is different from a 36-hour extended fast.
• No acute illness. Infection and systemic inflammation suppress IGF-1 acutely. Wait at least two weeks after resolution before drawing.

The Endocrine Society's 2019 guidelines on GH testing state: "IGF-1 measurement should be performed in a reference laboratory using a validated assay, and results should be interpreted relative to age- and sex-matched normative data." [20]

Interpreting a Low IGF-1: Nutritional vs. Pathological Suppression

Not every low IGF-1 means GH deficiency or a problem with your peptide protocol. The differential for a low IGF-1 includes:

• Nutritional suppression (most common in telehealth/longevity patients): low caloric intake, low protein, or recent fasting.
• Hypothyroidism: thyroid hormone is required for normal GH receptor expression in the liver. A suppressed TSH or low free T4 can lower IGF-1 by 20 to 40%.
• Poorly controlled type 1 diabetes: chronic insulin deficiency impairs hepatic IGF-1 synthesis despite normal or elevated GH.
• Liver disease: cirrhosis or significant hepatic fibrosis reduces the liver's synthetic capacity for IGF-1.
• True adult GH deficiency: confirmed by GH stimulation testing (insulin tolerance test or glucagon stimulation), not by a single IGF-1 alone. [20]

A low IGF-1 drawn two weeks into an 800-kcal deficit does not warrant an MRI of the pituitary. It warrants a repeat draw under stable nutritional conditions.

Practical Takeaways for Patients on GH or Peptide Protocols

Patients pursuing IGF-1 optimization through sermorelin, ipamorelin/CJC-1295, tesamorelin, or MK-677 (ibutamoren) should understand three facts before interpreting their labs:

1. Protein intake below 1.0 g/kg/day will blunt any peptide's IGF-1 response. Aim for at least 1.2 g/kg/day on dosing days.
2. Draw labs under stable conditions, not mid-diet-cut or during an extended fasting protocol.
3. The target range endorsed by the Endocrine Society for treated GH-deficient adults is the upper half of the age-adjusted normal range. For most adults aged 40 to 65 following a peptide protocol for body composition or longevity, that corresponds to approximately 180 to 260 ng/mL.

A 2023 review in the Journal of Clinical Endocrinology and Metabolism noted: "Nutritional optimization remains an underappreciated adjunct to GH-axis therapy; amino acid availability at the hepatic level may limit IGF-1 generation as much as pituitary GH output." [21]

For patients whose IGF-1 remains below 150 ng/mL after 12 weeks of peptide therapy with confirmed adequate protein intake, the next step is a full GH stimulation test to rule out true somatotroph deficiency, not a reflexive dose increase. Adults with confirmed GH deficiency by stimulation testing showed mean IGF-1 increases of 112 ng/mL after 6 months of recombinant human GH at 0.2 to 0.6 mg/day in a randomized trial by Carroll et al. (N=166), with lean mass gains of 3.1 kg vs. 0.4 kg placebo (P<0.001). [22]